AccuStem Sciences, Inc. 是一家临床阶段的诊断公司,从事医疗执业活动。公司总部位于纽约州纽约市,目前拥有2名全职员工。该公司于2022年3月1日上市。公司致力于开发和商业化一系列基因组检测产品,以支持肿瘤治疗全流程中的决策。公司专注于其专有的基因组检测,包括用于肺部结节患者的MicroRNA特征分类器(MSC)和用于早期乳腺癌患者的StemPrintER。MSC检测是一种包含24个microRNA(miRNA)的检测方法,旨在帮助确定通过低剂量计算机断层扫描(LDCT)筛查发现的肺部结节是良性还是恶性。StemPrintER是一种20个基因的预后检测方法,旨在预测腔内型(ER+/HER2阴性)乳腺癌患者远处复发(DR)的风险。该检测方法旨在测量肿瘤的干细胞性(stemness),即肿瘤表现得像干细胞的程度,这可能表明癌症复发或对标准治疗产生耐药性的可能性,最终影响患者多学科护理团队的管理方式。
ACUT stock price ended at $0.28 on 星期五, after dropping 12.50%
On the latest trading day Apr 24, 2026, the stock price of ACUT fell by 12.50%, dropping from $0.28 to $0.28. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.28 and a high of $0.28. On the latest trading day, the trading volume for ACUT rose by 1.5K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 1.6K shares were traded, with a market value of approximately $4.4M.